The financials
TG Therapeutics, Inc. by the numbers
TG Therapeutics, Inc. (TGTX) reported revenue of $240M in Q2 2026 (quarter ended June 30, 2026), up 70% from the same quarter a year earlier. That came with a gross margin of 83% and net income of $7.8M (3.2% of revenue). For the full year FY2025, revenue was $616M (+87% year on year) and net income $447M. Its largest product in 2026-Q2 was License at $4.5M, 50.0% of the disclosed total, just ahead of License at 50.0%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $240M | $141M | +70% |
| Gross profit | $199M | $122M | +63% |
| Operating income | $22M | $35M | −38% |
| Net income | $7.8M | $28M | −72% |
| Diluted EPS | $0.05 | $0.17 | −71% |
| Product | Revenue | Share |
|---|---|---|
| License | $4.5M | 50% |
| License | $4.5M | 50% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $9.1M (+26%)
License grew +97% year on yearLicense +97% year on year
Segment Latestquarter on quarteryear on year
- License$4.5M$4.5MQoQ +26%year on year +97%+26%+97%
- License$4.5M$4.5MQoQ +26%year on year +97%+26%+97%
- Royalty--QoQ -year on year ---